SCHEMBL4968152

SCHEMBL4968152

ON(CCc1ccccc1)CCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.62
CYP3A4 P08684 2/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C9 P11712 1/20 0.62
CYP2C19 P33261 1/20 0.62
TAAR1 Q96RJ0 1/20 0.58
AOC3 Q16853 2/20 0.54
TDP1 Q9NUW8 2/20 0.52
ALOX5 P09917 3/20 0.52
OPRK1 P41145 1/20 0.50
MEN1 O00255 1/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
KMT2A Q03164 1/20 0.50
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
ALOX12 P18054 1/20 0.48
CASP1 P29466 1/20 0.48
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8606673 0.88 CYP1A2 (0.79) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL7075328 0.86 AOC3 (0.59) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL10932714 0.85 ALOX5 (0.58) AOC3ALOX5SIGMAR1
SCHEMBL135744 0.84 TAAR1 (0.58) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL29013885 0.84 SIGMAR1 (0.49) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL27210158 0.83 SIGMAR1 (0.61) ALOX5SIGMAR1
SCHEMBL27210146 0.81 SIGMAR1 (0.64) ALOX5SIGMAR1
SCHEMBL30575705 0.81 CYP1A2 (0.50) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL28422310 0.80 TAAR1 (0.67) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL9353620 0.78 TAAR1 (0.52) CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4602020-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING Ecolab USA, Inc. (US) 2025-08-20 EP claimed
US-20240141131-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING ECOLAB USA INC. 2024-05-02 US claimed
WO-2024081354-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING ECOLAB USA INC. (US) 2024-04-18 WO claimed
EP-4602020-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING Ecolab USA, Inc. (US) 2025-08-20 EP disclosed
US-20240141131-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING ECOLAB USA INC. 2024-05-02 US disclosed
WO-2024081354-A1 ANTIPOLYMERANT COMPOSITIONS WITH NAPHTHOQUINONE AND HYDROXYLAMINE AND METHODS OF USING ECOLAB USA INC. (US) 2024-04-18 WO disclosed
US-9633755-B2 Conductive composition, conductive member, conductive member production method, touch panel, and solar cell FUJIFILM CORPORATION (JP) 2017-04-25 US disclosed
US-20080315155-A1 Diamines Having Reduced Color ALBEMARLE CORPORATION (US) 2008-12-25 US disclosed
US-20080262187-A1 Blends of Diamines Having Reduced Color ALBEMARLE CORPORATION (US) 2008-10-23 US disclosed
EP-1966122-A1 DIAMINES HAVING REDUCED COLOR Albermarle Corporation (US) 2008-09-10 EP disclosed
EP-1966265-A2 BLENDS OF DIAMINES HAVING REDUCED COLOR Albermarle Corporation (US) 2008-09-10 EP disclosed
US-5840984-A Stabilization of (hydrocarbylthio) aromatic amines against odor formation ALBEMARLE CORPORATION (US) 1998-11-24 US disclosed
EP-0839798-A2 Intermediates for preparating non-peptide retroviral protease inhibitors ABBOTT LABORATORIES (US) 1998-05-06 EP disclosed
US-5670675-A Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1997-09-23 US disclosed
US-5545750-A TREATING HUMAN IMMUNODEFICIENCY VIRUS ABBOTT LABORATORIES (US) 1996-08-13 US disclosed
US-5142056-A Human immunodeficiency virus protease inhibitor ABBOTT LABORATORIES (US) 1992-08-25 US disclosed
EP-0402646-A1 Retroviral protease inhibiting compounds ABBOTT LABORATORIES (US) 1990-12-19 EP disclosed
EP-0046271-B1 PHOTOSENSITIVE COMPOSITIONS AND ELEMENTS CONTAINING SUBSTITUTED HYDROXYLAMINE E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-10-19 EP disclosed
EP-0046271-A1 Photosensitive compositions and elements containing substituted hydroxylamine E.I. DU PONT DE NEMOURS AND COMPANY (US) 1982-02-24 EP disclosed
US-4298678-A PHOTOOXIDANT AND LEUCO DYE E. I. DU PONT DE NEMOURS AND COMPANY (US) 1981-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080262187-A1 Blends of Diamines Having Reduced Color DDT, DDC, AOC1 CYP1A2 524/4885CYP3A4 1488/4885CYP2D6 627/4885
US-20080315155-A1 Diamines Having Reduced Color DDT, DPYD, DDC CYP1A2 821/4885CYP3A4 2145/4885CYP2D6 1003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.